Pulmisonide Respules

Composition: Each 2ml inhalation suspension contains Budesonide 0.5mg in 2ml pack.

Formulation: Nasal spray, suspension

Category:

Therapy/Class:

Therapy:
Topical Nasal Corticosteroids
Class:
Locally Acting Intestinal Anti-inflammatory Agents

Mechanism of Action:

It is a topical anti-inflammatory effect on the nasal mucosa. It acts on wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic mediated inflammation. They also reduce cytokines, leukotrienes and chemokines (e.g. IL-1 to IL-6, RANTES, TNF-α, IFN-γ and GM-CSF) which are secreted by inflammatory cells. It binds to glucocorticoid receptors resulting in a complex which acts as a transcription factor by either down-regulating proinflammatory mediators or up-regulating anti-inflammatory mediators.

Indications:

  • Treatment and prevention of signs and symptoms of seasonal and perennial allergic rhinitis.
  • Treatment of signs and symptoms of nasal polyps.

Dosage & Administration:

  • 2 actuations into each nostril once daily in the morning or 1 actuation into each nostril in the morning and in the evening.

HOW SUPPLIED: PULMISONIDE RESPULES is available as inhalation suspension 2ml pack.

References:

  1. Mellon, M., & Budesonide Inhalation Suspension Study Group. (1999). Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. Journal of allergy and clinical immunology, 104(4), S191-S199.
  2. Bateman, E. D., Reddel, H. K., O’Byrne, P. M., Barnes, P. J., Zhong, N., Keen, C., … & FitzGerald, J. M. (2018). As-needed budesonide–formoterol versus maintenance budesonide in mild asthma. New England Journal of Medicine, 378(20), 1877-1887.
  3. Pedersen, S., Steffensen, G., Ekman, I., Tönnesson, M., & Borgå, O. (1987). Pharmacokinetics of budesonide in children with asthma. European journal of clinical pharmacology, 31, 579-582.
error: Content is protected !!